NIOX Group PLC
82C
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
Edmund Halley Road
Hayakawa Building
The Oxford Science Park
OxfordOX4 4GB
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
Vote in favour of merger for undervalued ASX share
We recommend shareholders vote in favor of its proposed merger.
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,557.40 | 11.70 | -0.14% |
| CAC 40 | 7,716.54 | 81.80 | 1.07% |
| DAX 40 | 20,874.18 | 218.79 | 1.06% |
| Dow JONES (US) | 43,153.13 | 68.42 | -0.16% |
| FTSE 100 | 8,508.03 | 116.13 | 1.38% |
| HKSE | 19,584.06 | 61.17 | 0.31% |
| NASDAQ | 19,338.29 | 172.95 | -0.89% |
| Nikkei 225 | 38,451.46 | 121.14 | -0.31% |
| NZX 50 Index | 13,130.43 | 129.76 | 1.00% |
| S&P 500 | 5,937.34 | 12.57 | -0.21% |
| S&P/ASX 200 | 8,310.40 | 16.60 | -0.20% |
| SSE Composite Index | 3,241.82 | 5.79 | 0.18% |